Drug Information

Drug General Information
Drug ID
D0X3TI
Former ID
DNCL002922
Drug Name
SRT3025
Indication Type 2 diabetes [ICD9: 250; ICD10:E11] Phase 1 [523447]
Company
Sirtris
Target and Pathway
Target(s) NAD-dependent deacetylase sirtuin-1 Target Info Modulator [533296]
KEGG Pathway FoxO signaling pathway
AMPK signaling pathway
Glucagon signaling pathway
Amphetamine addiction
MicroRNAs in cancer
PANTHER Pathway p53 pathway
Pathway Interaction Database p73 transcription factor network
Signaling events mediated by HDAC Class III
E2F transcription factor network
HIF-2-alpha transcription factor network
Signaling events mediated by HDAC Class I
FoxO family signaling
Regulation of Androgen receptor activity
Regulation of retinoblastoma protein
Reactome RORA activates gene expression
Regulation of HSF1-mediated heat shock response
Circadian Clock
WikiPathways Integrated Pancreatic Cancer Pathway
SREBF and miR33 in cholesterol and lipid homeostasis
Integrated Breast Cancer Pathway
SREBP signalling
Androgen receptor signaling pathway
References
Ref 523447ClinicalTrials.gov (NCT01340911) A Study in Healthy Male Volunteers to Investigate Different Doses of a New Drug for the Treatment of Metabolic Diseases. U.S. National Institutes of Health.
Ref 533296The Sirt1 Activators SRT2183 and SRT3025 Inhibit RANKL-Induced Osteoclastogenesis in Bone Marrow-Derived Macrophages and Down-Regulate Sirt3 in Sirt1 Null Cells. PLoS One. 2015 Jul 30;10(7):e0134391.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.